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Acute bronchitis accounts for 80% of lower respiratory tract infec­
tions (LRTIs), and despite evidence that antibiotics are of little or no 
benefit, up to 80% of patients are prescribed them.[1] A high incidence 
of infectious diseases and frequent use of antibiotics are reported 
from low­ and middle­income countries (LMICs), where resistant 
bacteria spread rapidly owing to factors such as overcrowding, 
poor sanitation and a warm, humid climate.[2­4] Although acute 
bronchitis should be differentiated from more severe illness that 
may require antibiotics, including pneumonia,[5] disease­focused 
solutions address the limited value of medical history­taking and 
physical examination in differentiating between pneumonia and 
self­limiting acute bronchitis.[6­8] Moreover, diagnostic uncertainty 
has encouraged general practitioners to prescribe antibiotics, since 
routinely requesting a chest radiograph for patients with LRTIs is 
neither feasible nor appropriate in most primary care centres.[1]
Although several clinical scoring systems have been used to assess 
the severity of LRTIs and predict the patient’s prognosis, very few 
have included management of acute bronchitis.[9] The Bronchitis 
Severity Score (BSS), first described in 1996 by Haidvogl et al.,[10] 
is a clinical assessment scale based on physician­assessed items 
in conjunction with subjective feedback from the patient. It was 
designed to be used by primary healthcare practitioners to assess the 
clinical status of a patient with acute bronchitis at various points of 
time, i.e. baseline and follow­up visits.
Objectives
To assess the validity of the BSS in assessing the clinical response to 
treatment of acute bronchitis in Egyptian children; and to determine 
whether simple laboratory measurements would help to identify 
patients with acute bronchitis who need an antibiotic, and indicate 
the possibility of a bacterial cause of the bronchitis.
Methods
Study setting and design
We used a cross­sectional study design, with a convenience sample 
collected from the general paediatric outpatient clinic at a university 
hospital. From January to May 2009, 200 patients were included 
consecutively at their first consultation with the participating 
paediatricians. Individual duration of the study was 7 days. During 
this time, three visits were scheduled for each patient (day 0, day 5 
and day 7). Children aged 6 months ­ 12 years who had a clinically 
based diagnosis of acute bronchitis and a BSS of ≥5 were eligible 
to participate in the study. Those who had received treatment with 
antibiotics during the 2 weeks prior to the first study visit, those 
with symptoms suggestive of other potential causes of cough, such as 
allergic rhinitis, sinusitis, recurrent wheezing or asthma, and those 
with serious medical comorbidities such as congenital malformations, 
immunodeficiencies and heart disease were excluded. Furthermore, 
eligible patients were not enrolled if their caregivers were unwilling or 
unable to participate or if they lived away from the study area, making 
follow­up impractical. Study participants were classified according 
to their age into three groups: group 1 (infants), group 2 (preschool 
children) and group 3 (middle childhood).
Ethical considerations
Ethics approval was granted by the Institutional Review Board of the 
New Children’s Hospital (Abou el Reesh), the specialist paediatric 
hospital of Cairo University, before the study started (no reference 
number). Informed consent was obtained from all parents or patients’ 
guardians before they were enrolled in the study. Verbal assent was 
obtained from patients aged >7 years. The study objectives and 
procedures were explained, and guardians were reassured about the 
confidentiality of the study data.
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Study measurements
A detailed history was taken in all cases, 
with special emphasis on fever, cough, associ­
ated symptoms (e.g. stridor, hoarseness of 
voice, wheezing and dyspnoea) and a history 
of smoking by family members. A thorough 
chest examination was performed to confirm 
the diagnosis and exclude similar conditions. 
The BSS measured cough, sputum, rales/
rhonchi, chest pain during coughing, and 
dyspnoea. Each of these features of acute 
bronchitis was scored by a well­trained 
doctor using a 5­point Likert rating scale 
ranging from 0 to 4 (0 = absent, 1 = mild, 
2 = moderate, 3 = severe, 4 = very severe). 
The overall BSS was graded as mild (0 ­ 7), 
moderate (8 ­ 14) and severe (15 ­ 20).
Laboratory investigations
Full blood counts (FBCs) were performed on 
an ADVIA 60 Hematology Analyzer (Bayer 
Diagnostics, UK). C­reactive protein (CRP) 
was tested for using a CRP Latex Test Kit 
(Biotec Laboratories, UK). To measure the 
erythrocyte sedimentation rate (ESR), 2 mL 
of venous blood was collected according 
to the Westergren method into a tube con­
taining 0.5 mL sodium citrate. Blood cultures 
and sensitivity testing, only for patients with 
a temperature of ≥39oC, were done using a 
Bactec 9050 Blood Culture System (Becton 
Dickinson, USA).
No antibiotics were prescribed during the 
study period. The patients received symp­
tomatic treatment in the form of antipyret­
ics, cough medications and safe remedies. In 
patients who initially presented with high­
grade fever, the FBC and ESR were repeated.
Outcome measures
The main outcome measure was the initial 
BSS on presentation and the change in the 
BSS after 7 days.
Statistical analysis
A standard computer program, SPSS for 
Windows, release 16.0 (SPSS Inc., USA), 
was used for data entry and analysis. All 
quantitative variables were expressed as 
means with standard deviations (SDs). The 
Kruskal­Wallis test was used to estimate 
differences in quantitative values, the χ² test 
to compare the frequency of qualitative 
values among the different study groups, and 
Spearman’s correlation test for correlating 
non­parametric variables. For all tests, 
p<0.05 was considered significant.
Results
The demographic characteristics of the 
participants are shown in Table 1. The mean 
age of the children was 4.1 years, with the 
majority aged 2 ­ 5 years (45%). There were 
significantly more boys than girls (p˂0.02), 
with a male/female ratio of 1.3:1. Children 
living in suburban regions had a significantly 
increased incidence of acute bronchitis 
(p˂0.001).
Initial visit (day 0)
Clinical features of the study participants 
on day 0 are summarised in Fig. 1. Of the 
patients, 124 (62%) were found to have 
an elevated temperature, with hyperthermia 
(≥38.9oC) in 36 children (18%) (Fig. 2). 
An acute cough was the main symptom 
in all cases, coughing being particularly 
severe in preschool children. A frequent dry, 
unproductive cough was reported in 72% of 
patients. Auscultation revealed rhonchi in 42 
children (21%).
Based on the BSS, 47% of patients had 
moderate disease activity on initial presen­
tation, with a mean (SD) overall score of 
8.36 (2.6) (Fig. 3), and 14% of patients were 
classified as severe.
The results of blood tests on day 0 
are set out in Table 2. At the initial visit, 
12  children (6%) had showed leucocyto­
sis, 6 (3%) bandaemia and 104 (52%) 
lympho cytosis (Table 3). The ESR ranged 
from 8 to 45 mm/h, with a mean of 15.88 
(7.9) mm/h. CRP was mildly elevated 
in four children, all in the infant group, 
with titres ranging from 6 to 12 mg/L 
(normal up to 4 mg/L). Blood culture and 
sensitivity testing, done only for patients 
who presented with high­grade fever (4%), 
revealed no growth.
Table 1. Demographic characteristics of 
the study population (N=200)
Characteristics Patients, n (%)
Sex
Male 112 (56.0)
Female 88 (44.0)
Age category
6 ­ 23 months (infants) 46 (23.0)
2 ­ 5 years (preschool) 90 (45.0)
 6 ­ 11 years (middle 
childhood)
64 (32.0)
Residence
Urban 42 (21.0)
Suburban 93 (46.4)
Rural 65 (32.5)
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Fig. 1. Manifestations of acute bronchitis on initial presentation.
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Fig. 2. Distribution of fever in the three age groups on initial presentation.
344       April 2017, Vol. 107, No. 4
RESEARCH
Primary outcome measures (day 5)
The mean (SD) BSS decreased to 4.03 (2.3) by the 5th day of 
treatment (Fig. 3). A wet cough and discharge of mucus were repor­
ted in 38 patients (19%), but the amount and frequency of sputum 
had decreased. The intensity of cough (day and night attacks) 
had decreased in 167 children (83.5%). The individual signs of 
rales/rhonchi had improved in 23 patients (11.5%). The fever had 
disappeared in 113 patients (56.5%). No investigations were done at 
this visit.
Secondary outcome measures (day 7)
Final assessment on day 7 included BSS evaluation, and laboratory 
tests in selected cases. The mean (SD) BSS had decreased to 2.36 
(1.45) (Fig. 3). The cough had completely disappeared in 132 patients 
(66%), had improved with production of a small amount of whitish 
mucoid sputum in 13 (6.5%), and was mild/dry in 55 (27.5%). On 
clinical examination, the fever had disappeared in all previously 
feverish patients. Rhonchi, audible in only three children, were 
associated with a mildly productive cough.
Blood tests showed normalisation of the number of lymphocytes 
and neutrophils and of the ESR in patients who had initially 
presented with hyperthermia.
Discussion
Our study confirmed that the diagnosis of acute bronchitis is 
influenced by variables such as cough, purulent sputum and the 
presence of abnormal chest findings on examination. Overall, 
our results are consistent with previously published research 
on childhood acute bronchitis,[11] with a predominance of acute 
cough in all cases. Twenty­eight percent of our participants had 
a productive cough with purulent sputum. These findings are 
consistent with other studies,[11,12] in which >50% of parents 
described the cough as dry, the remainder reporting it to be 
productive or of a mixed type. As has been reported by others,[13,14] 
we found that the colour of the sputum had no predictive value for 
the diagnosis of bacterial bronchitis or for differentiating between 
pneumonia and bronchitis.
Although fever is unusual in patients with acute bronchitis, 62% of 
our patients were initially febrile. During follow­up, fever subsided 
in all cases without antimicrobial treatment. Similar results were 
observed in a previous study,[15] where fever was reported in 66.6% 
of children. Further studies[16,17] showed a 96.4% rate of remission of 
fever with only antipyretic treatment.
Consistent with other studies,[11,18] 28% of our study participants, 
mainly preschool children, showed mild manifestations of upper 
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Table 3. Abnormal blood results in the three age groups on 
initial presentation
Infant 
(N=46),
n (%)
Preschool 
(N=90),
n (%)
Middle childhood 
(N=64),
n (%)
Anaemia* 42 (91.3) 84 (93.3) 34 (53.1)
Leucocytosis† 0 0 12 (18.8)
Lymphocytosis‡ 14 (30.4) 44 (48.9) 46 (71.9)
Bandaemia¶ 2 (4.3) 0 4 (6.2)
*Haemoglobin: norm l values 10.5 ­ 12.6 g/dL for infants, 11.5 ­ 12.5 g/dL preschool,  
11.5 ­ 13.5 g/dL middle childhood.
†Total WBC count: normal values 6 ­ 17 × 10³/µL for infants, 5 ­ 15.5 × 10³/µL preschool,  
4.5 ­ 13.5 × 10³/µL middle childhood.
‡Lymphocytes: normal values 9 ­ 61% of total WBCs for infants, 42 ­ 59% preschool,  
35 ­ 42% middle childhood.
¶Bandaemia: staff/segmented <0.2.
Table 2. Results of initial blood tests in the study groups
Infant
(N=46)
Preschool
(N=90)
Middle childhood
(N=64)
Hb (g/dL)
Normal range for age 10.5 ­ 12.6 11.5 ­ 12.5 11.5 ­ 13.5
Mean (SD) (range) 9.9 (1.2) (8 ­ 12) 10.8 (1.2) (8 ­ 13) 11.0 (1.4) (8 ­ 14)
Total WBC count (× 103/µL) 
Normal range for age 6 ­ 17 5 ­ 15.5 4.5 ­ 13.5
Mean (SD) (range) 10.8 (3.1) (5 ­ 16) 9.2 (3.3) (4 ­ 16) 9.9 (3.9) (5 ­ 18)
Neutrophils (%)
Normal range for age 31 ­ 33 33 ­ 51 51 ­ 54
Mean (SD) (range) 35.9 (11.2) (17 ­ 65) 39.2 (12.9) (12 ­ 72) 43.3 (17.1) (17 ­ 88)
Lymphocytes (%)
Normal range for age 59 ­ 1 42 ­ 59 35 ­ 42
Mean (SD) (range) 53.6 ( .2) (28 ­ 73) 52.7 (13.4) (23 ­ 75) 47.3 (16.9) (7 ­ 73)
Band/segmented (× 103/µL) 
Normal range for ag <0.2 <0.2 <0.2
Mean (SD) 0.05 (0.04) 0.05 (0.04) 0.04 (0.04)
Hb = haemoglobin.
Fig. 3. Mean BSS at different time points (day 0, day 5, day 7).
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respiratory tract infections (e.g. nasal discharge, pharyngitis, 
nasopharyngitis) during the initial visit.
Our study shows that the BSS is valuable as a simple index for 
scoring acute bronchitis in children. The mean BSS at the initial 
visit revealed moderate severity of bronchitis. This is consistent with 
the results of a previous study,[19] where the mean (SD) BSS was 12 
(1.5).[19] By day 7, our mean BSS score had decreased to 2.36 (1.45). 
Similar results were reported from studies conducted in Ukraine and 
Germany.[20,21]
Investigations such as the total white blood cell (WBC) count, 
CRP and ESR have consistently been found to be one of the strongest 
determinants of antibiotic prescription.[21] In a Japanese trial of 
outpatients with febrile acute bronchitis, measurement of WBCs was 
associated with a much lower rate of antibiotic prescription compared 
with usual care that depends only on clinical assessment.[22] A study 
in The Netherlands[1] found that the use of CRP significantly reduced 
antibiotic prescription for LRTIs.
In the present study, we were unable to establish significant 
correlations between the WBC count, CRP, ESR and the grade of 
fever (p˃0.05). This suggests that more studies are needed for better 
understanding of the context in which these investigations could be 
used to indicate whether an antibiotic is necessary.
In our study, even febrile children received only symptomatic 
treatment. Similar results were observed in a study carried out in 
Europe,[22] where patients were divided into two groups. The first 
group received azithromycin, while the second group received low­
dose vitamin C. Outcomes at days 3 and 7 showed no difference 
between two groups, with clinical improvement in 89% of cases.
To our knowledge, only a few studies[18,20] have examined the 
validity of the BSS in assessing severity of acute bronchitis in 
children. Our findings are consistent with this previous research, 
which showed BSS to be a suitable index for use in children with 
acute bronchitis, including in LMICs.
Study limitations
Our study has a number of limitations, a major one being the 
validation of the BSS in the absence of a definite diagnosis of acute 
bronchitis. It was therefore difficult to evaluate the score in terms of 
sensitivity and specificity as regards clinical improvement or failure. 
Furthermore, all outcomes of the current study were subjective. 
Finally, the study was conducted in a single centre, where the study 
sample was not representative of the whole childhood population.
Recommendations
We identified the BSS as a simple and practical clinical scoring 
system useful in evaluating disease severity and monitoring disease 
resolution in acute bronchitis. It may therefore also help to decrease 
the injudicious use of antimicrobial agents and thereby combat 
antibiotic resistance. Our findings suggest that general practitioners 
and healthcare providers in primary healthcare units should be 
focused on in an effort to change their prescribing practices. 
Our findings also highlight the need for the development and 
implementation of national strategic plans to treat respiratory tract 
infections across all LMICs.
Conclusions
Acute bronchitis in children is a mild and self­limiting disease that 
rarely warrants antibiotic treatment. The most important condition 
to be ruled out before establishing the diagnosis of acute bronchitis 
is pneumonia. Increased awareness of the BSS will help in reducing 
unnecessary antibiotic prescription and thereby antimicrobial resis­
tance. It should also be recognised that the presence of fever and/or 
coloured sputum is not an absolute indication of bacterial infection. 
Laboratory investigations and blood culture should be considered if 
a bacterial cause is suspected and supported by the clinical findings. 
Future research is needed to further validate the BSS.
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